Last reviewed · How we verify
150-day taper prednisone
At a glance
| Generic name | 150-day taper prednisone |
|---|---|
| Sponsor | VA Office of Research and Development |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
- CROHN'S DISEASE
- ARTHRALGIA
- NASOPHARYNGITIS
- ABDOMINAL PAIN
- HEADACHE
- PYREXIA
- FATIGUE
- OROPHARYNGEAL PAIN
- RASH
- INFLUENZA
- ALOPECIA
- ANAEMIA
Key clinical trials
- Orelabrutinib in the Treatment of Relapsed/Refractory AIHA (PHASE2)
- Study in Human iPSCs-derived RPE Cells Transplantation for Late-Stage AMD (PHASE1, PHASE2)
- Dynamic Treatment Regiments for Glucocorticoid Tapering (PHASE2)
- Rituximab and Targeted Nursing for Pediatric Nephrotic Syndrome (NA)
- Azathioprine in MOGAD (PHASE3)
- Optimum Immunosuppression in Renal Transplant Recipients.New Onset Diabetes After Transplantation (PHASE4)
- Evaluation of Efficacy and Safety of Sarilumab in Patients With GCA (PHASE3)
- Proportion of CMV Seropositive Kidney Transplant Recipients Who Will Develop a CMV Infection When Treated With an Immunosuppressive Regimen Including Everolimus and Reduced Dose of Cyclosporine Versus an Immunosuppressive Regimen With Mycophenolic Acid and Standard Dose of Cyclosporine A (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |